연구용
Ganciclovir sodium CMV 억제제
제품 번호S5065
화학 구조
분자량: 277.21
바로가기
품질 관리
배치:
순도:
99.96%
99.96
세포 배양, 처리 및 작업 농도
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| CEM | Cytotoxicity assay | Cytotoxicity against CEM cells, CC50 = 5 μM. | 15615545 | |||
| bone marrow cells | Cytotoxicity assay | 15 days | Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days, CC50 = 30 μM. | 17329103 | ||
| RG2TK+ | Cytotoxicity assay | 72 hrs | Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay, CC50 = 5.86 μM. | 18800764 | ||
| HFF | Function assay | Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells, EC50 = 0.5 μM. | 8394933 | |||
| Vero | Function assay | Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%, EC50 = 0.23 μM. | 11585457 | |||
| MRC-5 | Function assay | Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells., EC50 = 9.4 μM. | 12723951 | |||
| HEL | Function assay | Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50 = 0.06 μM. | 14643328 | |||
| HFF | Function assay | Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay, EC50 = 2.1 μM. | 15615545 | |||
| HFF | Function assay | Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay, EC50 = 2.2 μM. | 15615545 | |||
| H-1 | Function assay | Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM. | 15615545 | |||
| H-1 | Function assay | Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay, EC50 = 5 μM. | 15634003 | |||
| Hel | Function assay | Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells, EC50 = 0.06 μM. | 15658858 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.06 μM. | 16392791 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in HEL cells, EC50 = 0.06 μM. | 16392791 | |||
| HFF | Function assay | Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay, EC50 = 0.15 μM. | 17004726 | |||
| HFF | Function assay | Inhibition of HCMV towne replication in HFF cells by plaque reduction assay, EC50 = 1.8 μM. | 17004726 | |||
| H1 | Function assay | Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM. | 17004726 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.019 μM. | 17181162 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 in HEL cells, EC50 = 0.032 μM. | 17181162 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.48 μM. | 17181162 | |||
| CCL81 | Antiviral assay | Antiviral activity against HSV2 in CCL81 cells, EC50 = 1.5 μM. | 17188402 | |||
| CCL81 | Antiviral assay | Antiviral activity against HSV1 in CCL81 cells, EC50 = 1.5 μM. | 17188402 | |||
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 0.7 μM. | 17438061 | ||
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 14.5 μM. | 17438061 | ||
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 19.2 μM. | 17438061 | ||
| Vero | Antiviral assay | 36 to 48 hrs | Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 23.5 μM. | 17438061 | ||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation, EC50 = 2.75 μM. | 17518459 | |||
| HEL | Antiviral assay | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation, EC50 = 6.3 μM. | 17518459 | |||
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days, EC50 = 1.3 μM. | 17539622 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days, EC50 = 4.8 μM. | 17539622 | ||
| HEL | Antiviral assay | 5 days | Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days, EC50 = 2.3 μM. | 17622128 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 5.1 μM. | 17622128 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 8.7 μM. | 17622128 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against CMV Davis in human HEL cells after 7 days, EC50 = 2.6 μM. | 17672445 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against CMV AD169 in human HEL cells after 7 days, EC50 = 6.5 μM. | 17672445 | ||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50 = 1.1 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.6 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.7 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.5 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.9 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.1 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.6 μM. | 17709468 | |||
| HFF | Antiviral assay | Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 8.4 μM. | 17709468 | |||
| HEL | Antiviral assay | 3 days | Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 1.3 μM. | 17961851 | ||
| HEL | Antiviral assay | 3 days | Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 4.8 μM. | 17961851 | ||
| HFF | Antiviral assay | Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay, EC50 = 2.5 μM. | 18082410 | |||
| hhTERT-BJ1 | Antiviral assay | 2 days | Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days, EC50 = 3 μM. | 18458124 | ||
| NIH 3T3 | Antiviral assay | 4 to 5 days | Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay, EC50 = 5.7 μM. | 18458124 | ||
| HEL | Antiviral assay | Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.66 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.69 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.7 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM. | 19226140 | |||
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 2 μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.6 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 3.5 μM. | 19226140 | |||
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 3.6 μM. | 19226140 | ||
| HEL | Antiviral assay | Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4.3 μM. | 19226140 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.02 μM. | 19281225 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.2 μM. | 19281225 | |||
| feline FRCK | Antiviral assay | Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM. | 19281225 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 9 μM. | 19281225 | |||
| HEL | Antiviral assay | 5 days | Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 0.59 μM. | 19339082 | ||
| HEL | Antiviral assay | 5 days | Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days, EC50 = 1.1 μM. | 19339082 | ||
| HEL | Antiviral assay | 5 days | Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 2.5 μM. | 19339082 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 2.5 μM. | 19339082 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 12.6 μM. | 19339082 | ||
| foreskin fibroblast cells | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. | 19397271 | |||
| foreskin fibroblast cells | Antiviral assay | Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay, EC50 = 1.2 μM. | 19397271 | |||
| embryonic fibroblast cells | Antiviral assay | Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay, EC50 = 5.5 μM. | 19397271 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| Vero | Antiviral assay | Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. | 19858259 | |||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. | 20034711 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. | 20034711 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. | 20034711 | ||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay, EC50 = 2.6 μM. | 20034711 | |||
| HS27 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 0.32 μM. | 20047911 | ||
| MRC5 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 1.65 μM. | 20047911 | ||
| HEL299 | Antiviral assay | 7 days | Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 2.39 μM. | 20047911 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.05 μM. | 21128666 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.08 μM. | 21128666 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 3 μM. | 21128666 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 5.2 μM. | 21128666 | ||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.01 μM. | 21232828 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. | 21232828 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM. | 21232828 | |||
| HFF | Antiviral assay | 1 hr | Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50 = 0.04 μM. | 21376429 | ||
| HEL | Antiviral assay | Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.027 μM. | 21565516 | |||
| HEL | Antiviral assay | Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.03 μM. | 21565516 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6 μM. | 21565516 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6.54 μM. | 21565516 | |||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity, EC50 = 8.1 μM. | 21565516 | |||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 15.7 μM. | 21565516 | |||
| HEL | Antiviral assay | 4 days | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM. | 21696963 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM. | 21696963 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.8 μM. | 21696963 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.02 μM. | 22459876 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.03 μM. | 22459876 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM. | 22459876 | ||
| HEL | Antiviral assay | 4 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM. | 22459876 | ||
| CRFK | Antiviral assay | 4 days | Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay, EC50 = 4.1 μM. | 22459876 | ||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.1 μM. | 22578783 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.5 μM. | 22578783 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 0.027 μM. | 22858222 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay, EC50 = 0.029 μM. | 22858222 | |||
| CRFK | Antiviral assay | Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay, EC50 = 1.15 μM. | 22858222 | |||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay, EC50 = 5.9 μM. | 22858222 | |||
| HEL | Antiviral assay | Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay, EC50 = 9.1 μM. | 22858222 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 14.7 μM. | 22858222 | |||
| CRFK | Antiviral assay | 3 days | Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days, EC50 = 1.2 μM. | 23047229 | ||
| HEL | Antiviral assay | Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.013 μM. | 23099097 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.015 μM. | 23099097 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4 μM. | 23099097 | |||
| HEL | Antiviral assay | Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM. | 23795238 | |||
| HEL | Antiviral assay | Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM. | 23795238 | |||
| HEL | Antiviral assay | Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 1 μM. | 23795238 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. | 23811093 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. | 23811093 | |||
| HEL | Antiviral assay | Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 4 μM. | 23811093 | |||
| CRFK | Antiviral assay | Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay, EC50 = 4.1 μM. | 23811093 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation, EC50 = 5.98 μM. | 23811093 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation, EC50 = 7.87 μM. | 23811093 | |||
| HEL | Antiviral assay | Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after, EC50 = 8.2 μM. | 23911854 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 0.38 μM. | 23911856 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.9 μM. | 23911856 | |||
| CRFK | Antiviral assay | Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay, EC50 = 0.9 μM. | 23911856 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 3.1 μM. | 23911856 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.02 μM. | 26001344 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. | 26001344 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.5 μM. | 26001344 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 6.3 μM. | 26001344 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 7.1 μM. | 26001344 | |||
| HEL | Antiviral assay | 7 days | Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 4.72 μM. | 26291038 | ||
| HEL | Antiviral assay | 7 days | Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 6.12 μM. | 26291038 | ||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 7.8 μM. | 26443550 | |||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 13.9 μM. | 26443550 | |||
| Vero | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 0.9 μM. | 26460883 | ||
| Vero | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 1.4 μM. | 26460883 | ||
| Vero | Antiviral assay | 3 days | Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 2.14 μM. | 26460883 | ||
| Vero | Antiviral assay | 3 days | Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 11.1 μM. | 26460883 | ||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD169 infected in HEL cells, EC50 = 0.25 μM. | 27128178 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells, EC50 = 0.4 μM. | 27128178 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.03 μM. | 27639368 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.09 μM. | 27639368 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 2.1 μM. | 27639368 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 3.1 μM. | 27639368 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.032 μM. | 27750154 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.055 μM. | 27750154 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 4 μM. | 27750154 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 6.5 μM. | 27750154 | |||
| HEL | Antiviral assay | Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 14.9 μM. | 27750154 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 8.7 μM. | 28682067 | |||
| HEL | Antiviral assay | Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 16.5 μM. | 28682067 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM. | 28757102 | |||
| HEL | Antiviral assay | Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. | 28757102 | |||
| HEL | Antiviral assay | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM. | 28757102 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 2.96 μM. | 28757102 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 6.79 μM. | 28757102 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM. | 28829913 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. | 28829913 | |||
| HEL | Antiviral assay | Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4.3 μM. | 28829913 | |||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.3 μM. | 28829913 | |||
| HEL | Antiviral assay | Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.4 μM. | 28829913 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 4.05 μM. | 29407990 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 5.63 μM. | 29407990 | |||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.019 μM. | 29550734 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.045 μM. | 29550734 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 3.91 μM. | 29550734 | ||
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 4.83 μM. | 29550734 | ||
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 6.46 μM. | 29550734 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.051 μM. | 29670705 | ||
| HEL | Antiviral assay | 2 to 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.057 μM. | 29670705 | ||
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 3.31 μM. | 29670705 | ||
| HEL | Antiviral assay | 6 to 7 days | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 7.41 μM. | 29670705 | ||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM. | 29880251 | |||
| HEL | Antiviral assay | Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM. | 29880251 | |||
| HEL | Antiviral assay | Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.8 μM. | 29880251 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.29 μM. | 29880251 | |||
| HEL | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 11.43 μM. | 29880251 | |||
| HELF | Antiviral assay | Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM. | 30098481 | |||
| HELF | Antiviral assay | Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM. | 30098481 | |||
| HELF | Antiviral assay | Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.5 μM. | 30098481 | |||
| HELF | Antiviral assay | Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 6.52 μM. | 30098481 | |||
| HELF | Antiviral assay | Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 11.75 μM. | 30098481 | |||
| HEL | Antiviral assay | 3 days | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM. | 30286952 | ||
| HEL | Antiviral assay | 3 days | Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM. | 30286952 | ||
| HEL | Antiviral assay | 3 days | Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.2 μM. | 30286952 | ||
| HFF | Antiviral assay | 5 to 7 days | Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay, EC99.9 = 5 μM. | 17329103 | ||
| MRC-5 | Antiviral assay | In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain), IC50 = 4 μM. | 1323678 | |||
| BSC-1 | Antiviral assay | Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50 = 3 μM. | 2913300 | |||
| HEL | Function assay | Inhibition of human CMV DNA synthesis in CMV-infected HEL cells., IC50 = 0.5 μM. | 7752205 | |||
| HEL | Function assay | Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR., IC50 = 7 μM. | 7752205 | |||
| BSC-1 | Antiviral assay | In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells., IC50 = 3.5 μM. | 9057865 | |||
| HFF | Antiviral assay | In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells., IC50 = 7.4 μM. | 9057865 | |||
| HFF | Antiviral assay | Antiviral activity was determined by the HCMV plaque assay using HFF cells, IC50 = 7.7 μM. | 9057866 | |||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay, IC50 = 2.6 μM. | 9438017 | |||
| MEF | Function assay | Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay, IC50 = 3.4 μM. | 9438017 | |||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. | 9438017 | |||
| MRC-5 | Function assay | Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells, IC50 = 6.3 μM. | 9836613 | |||
| BSC-1 | Antiviral assay | Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells, IC50 = 3.5 μM. | 10882370 | |||
| HFF | Antiviral assay | Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells, IC50 = 7.4 μM. | 10882370 | |||
| BSC-1 | Function assay | ELISA assay was performed using BSC-1 cells to determine activity against HSV-1, IC50 = 3.5 μM. | 10882372 | |||
| HFF | Antiviral assay | Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells, IC50 = 7.4 μM. | 10882372 | |||
| HFF | Function assay | Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.1 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.5 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells, IC50 = 7.4 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells, IC50 = 7.4 μM. | 10882375 | |||
| MRC-5 | Function assay | Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells, IC50 = 5.9 μM. | 10966740 | |||
| MRC5 | Function assay | Inhibitory concentration against Davis strain of HCMV in MRC5 cells, IC50 = 1.4 μM. | 11454465 | |||
| MRC5 | Function assay | Inhibitory concentration against Towne strain of HCMV in MRC5 cells, IC50 = 1.5 μM. | 11454465 | |||
| MRC5 | Function assay | Inhibitory concentration against 2599R strain of HCMV in MRC5 cells, IC50 = 1.6 μM. | 11454465 | |||
| MRC5 | Function assay | Inhibitory concentration against AD169 strain of HCMV in MRC5 cells, IC50 = 3 μM. | 11454465 | |||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. | 15509174 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. | 15509174 | |||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. | 15509175 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. | 15509175 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. | 15509176 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. | 15509176 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. | 15509176 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 2.5 μM. | 15509176 | |||
| BSC-1 | Function assay | Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. | 15509176 | |||
| HFF | Function assay | Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. | 15509176 | |||
| foreskin fibroblast cells | Antiviral assay | 1 hr | Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM. | 16134946 | ||
| foreskin fibroblast cells | Antiviral assay | 1 hr | Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM. | 16134946 | ||
| foreskin fibroblast cells | Antiviral assay | Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO, IC50 = 1.3 μM. | 16134946 | |||
| bone marrow cells | Cytotoxicity assay | Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50 = 30 μM. | 16814545 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay, IC50 = 1.3 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50 = 1.4 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay, IC50 = 1.4 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV AD169 in HFF cells by PRA, IC50 = 1.9 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2291 in HFF cells by PRA, IC50 = 4.1 μM. | 17043128 | |||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50 = 4.9 μM. | 17043128 | |||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV T2296 in MRC5 cells by PRA, IC50 = 5.4 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay, IC50 = 5.6 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay, IC50 = 7.1 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2293 in HFF cells by PRA, IC50 = 10 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2311 in HFF cells by PRA, IC50 = 12.4 μM. | 17043128 | |||
| MRC5 | Antiviral assay | Antiviral activity against Human CMV T2287 in MRC5 cells by PRA, IC50 = 30.1 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay, IC50 = 30.2 μM. | 17043128 | |||
| HFF | Antiviral assay | Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay, IC50 = 3 μM. | 17161946 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK, IC50 = 0.0019 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.018 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.033 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.041 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.05 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.081 μM. | 17181158 | |||
| OST TK-cells | Cytotoxicity assay | Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.11 μM. | 17181158 | |||
| MRC5 | Antiviral assay | Antiviral activity against HCMV in MRC5 cells by plaque reduction assay, IC50 = 0.91 μM. | 17239594 | |||
| HFF | Antiviral assay | 5 days | Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay, IC50 = 1 μM. | 17329103 | ||
| HFF | Antiviral assay | Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay, IC50 = 1.3 μM. | 17434304 | |||
| MCA-TK | Cytotoxicity assay | Cytotoxicity against MCA-TK cells, IC50 = 0.15 μM. | 17960926 | |||
| HFF | Antiviral assay | Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay, IC50 = 3.22 μM. | 19010684 | |||
| HFF | Antiviral assay | Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay, IC50 = 16.4 μM. | 19010684 | |||
| HFF | Antiviral assay | Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay, IC50 = 1.3 μM. | 20167488 | |||
| HFF | Function assay | Inhibition of HCMV DNA polymerase infected in HFF cells, IC50 = 1.3 μM. | 20403696 | |||
| HFF | Antiviral assay | 10 days | Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days, IC50 = 3 μM. | 21641218 | ||
| HFF | Antiviral assay | 10 days | Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay, IC50 = 0.14 μM. | 21812420 | ||
| HFF | Antiviral assay | 8 days | Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay, IC50 = 2.1 μM. | 22607883 | ||
| HFF | Function assay | In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells., IC90 = 1.6 μM. | 9057865 | |||
| HFF | Function assay | Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay, IC90 = 1.6 μM. | 9438017 | |||
| HFF | Antiviral assay | Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells, IC90 = 1.6 μM. | 10882370 | |||
| HFF | Antiviral assay | Antiviral activity against HCMV was determined by yield reduction assay using HFF cells, IC90 = 1.6 μM. | 10882372 | |||
| HFF | Function assay | Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells, IC90 = 1.6 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.3 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.6 μM. | 10882374 | |||
| HFF | Function assay | Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells, IC90 = 1.6 μM. | 10882375 | |||
| vero | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture, ID50 = 0.3 μM. | 2993615 | |||
| vero | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells., ID50 = 1.3 μM. | 2993615 | |||
| HCMV AD 169 | Antiviral assay | In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells., ID50 = 6 μM. | 2993615 | |||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-1(F) in Vero cells, ID50 = 0.2 μM. | 3009811 | |||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-2(G) in Vero cells, ID50 = 1.6 μM. | 3009811 | |||
| MRC5 | Antiviral assay | In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells, ID50 = 5 μM. | 3009811 | |||
| Vero | Antiviral assay | In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells, ID50 = 10 μM. | 3009811 | |||
| Vero | Antiviral assay | Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells, ID50 = 0.2 μM. | 3016263 | |||
| vero | Antiviral assay | Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain, ID50 = 0.2 μM. | 3871860 | |||
| E6SM | Antiviral assay | Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM. | 17092728 | |||
| E6SM | Antiviral assay | Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM. | 17092728 | |||
| E6SM | Antiviral assay | Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells, MIC = 0.8 μM. | 17092728 | |||
| HEL | Antiviral assay | Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.0064 μM. | 17672445 | |||
| HEL | Antiviral assay | Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.032 μM. | 17672445 | |||
| neural precursor cells | Function assay | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 17417631 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
화학 정보, 보관 및 안정성
| 분자량 | 277.21 | 화학식 | C9H12N5NaO4 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 107910-75-8 | -- | 원액 보관 |
|
|
| 동의어 | RS-21592 sodium, Cytovene IV sodium, BW 759 sodium, 2'-Nor-2'-deoxyguanosine sodium | Smiles | C1=NC2=C(N1COC(CO)CO)N=C(N=C2[O-])N.[Na+] | ||
용해도
|
In vitro |
DMSO
: 8 mg/mL
(28.85 mM)
Water : 6 mg/mL Ethanol : Insoluble |
몰농도 계산기
희석 계산기
분자량 계산기
|
In vivo |
|||||
생체 내 제형 계산기 (투명한 용액)
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
mg/kg
g
μL
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
작용 메커니즘
| 시험관 내(In vitro) |
Ganciclovir Sodium(RS-21592, Cytovene IV, BW 759, 2'-Nor-2'-deoxyguanosine)은 Ganciclovir의 나트륨염 형태로, 항바이러스 활성, 특히 거대세포바이러스(CMV)에 대한 활성을 가진 합성 항바이러스성 퓨린 뉴클레오사이드 유사체입니다. |
참조 |
|
|---|
임상시험 정보
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT06407232 | Not yet recruiting | Cytomegalovirus Infections|Kidney Transplant Infection|Pancreas Transplant |
University of Wisconsin Madison|Merck Sharp & Dohme LLC |
May 2024 | Phase 3 |
| NCT06057194 | Not yet recruiting | Infections Cytomegalovirus |
Maimónides Biomedical Research Institute of Córdoba|MERCK SHARP & DOHME DE ESPAÑA S.A. |
October 2023 | Phase 2 |
| NCT04706507 | Recruiting | Acute Respiratory Failure |
Fred Hutchinson Cancer Center|National Heart Lung and Blood Institute (NHLBI) |
June 29 2021 | Phase 3 |
| NCT04478474 | Completed | Cytomegalovirus Infections |
New York Medical College|Merck Sharp & Dohme LLC |
September 15 2020 | -- |
| NCT03698435 | Unknown status | Cytomegalovirus Infections |
University Medical Center Groningen |
May 25 2018 | -- |
기술 지원
제품은 연구용으로만 사용됩니다. 인체에는 사용하지 마십시오. 환자에게 판매하지 않습니다.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.